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Abstract: Acutely elevated blood pressure in the critical care setting is associated with a 
higher risk of acute end-organ damage (eg, myocardial ischemia, stroke, and renal failure) and 
  perioperative bleeding. Urgent treatment and careful blood pressure control are crucial to prevent 
significant morbidity. Clevidipine butyrate (Cleviprex) is an ultrashort-acting,   third-generation 
intravenous calcium channel blocker. It is an arterial-selective vasodilator with no venodilatory 
or myocardial depressive effects. Clevidipine has an extremely short half-life of approximately 1 
minute as it is rapidly metabolized by blood and tissue esterases. These metabolites are then 
primarily eliminated through urine and fecal pathways. The rapid onset and the short duration 
of action permit tighter and closer adjustment of the blood pressure than is possible with other 
intravenous agents.
Keywords: calcium channel blocker, antihypertensive medications, end-organ damage, 
  hypertensive crisis, hypertensive urgency
Introduction
Systemic hypertension is the most common cardiovascular condition, affecting as 
many as 1 billion people worldwide and responsible for 1 million deaths.1 It affects 
about 72 million individuals in the United States.2 According to American Heart 
  Association estimates, it is responsible for more than 54,000 deaths in 2004 in the 
US alone.3 The incidence of hypertensive emergency is disproportionately higher in 
the elderly, male, and African American populations.4 Approximately 1%–2% of all 
patients with hypertension are estimated to have hypertensive emergencies.2
The Joint National Committee on prevention, detection, evaluation, and treat-
ment of high blood pressure (JNC-7) publication defines hypertensive emergency 
as a severe elevation in blood pressure (BP) (usually .180/120 mmHg) compli-
cated by evidence of impending or progressive target organ dysfunction,5 such as 
neurologic changes, hypertensive encephalopathy, cerebral infarction, intracranial 
hemorrhage, myocardial ischemia or infarction, acute left ventricular dysfunc-
tion, acute pulmonary edema, aortic dissection, renal insufficiency, or eclampsia.6 
Hypertensive urgency is defined as “severe elevations in BP without progressive 
target organ dysfunction.”5 One study of emergency department admissions found 
that hypertensive crises accounted for 27.5% of all medical emergencies and urgen-
cies in patients arriving at an emergency department, with 77% having a history 
of hypertension.7Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Hypertension in critical care and 
perioperative surgical settings
In medical intensive care units (ICUs), the epidemiology of 
hypertensive urgency or hypertensive emergency has not been 
clearly defined, but appears to be frequent.8 Elevated BP during 
induction of anesthesia, intubation of the airway,   emergence 
from anesthesia, and extubation of the airway can result in 
hypertensive urgency. Furthermore, operative   procedures, 
including peripheral vascular surgery, coronary artery bypass, 
carotid endarterectomy, intracranial tumor resection, and 
aneurysm-clipping procedures, present other critical periods 
during which the strict control of BP is mandatory.6,9
Preoperative hypertensive emergencies, such as acute 
  aortic dissection, hypertension in pregnancy, and pheo-
chromocytoma, also require aggressive control of BP.6 
A   significant elevation in BP during the immediate postop-
erative period is defined as acute postoperative hyperten-
sion (APH) and may lead to multiple organ or surgical-site 
complications. APH has been observed within 2 hours after 
surgery in most cases.10 Postoperative hypertension is defined 
as a systolic blood pressure (SBP) .190 mmHg and/or dia-
stolic blood pressure (DBP) .100 mmHg on 2 consecutive 
readings after surgery.11
Acute perioperative hypertension affects up to 80% 
of patients undergoing cardiac surgery and up to 25% of 
patients undergoing major noncardiac surgery.12 Patients 
with perioperative hypertension commonly have a history of 
hypertension. Acute hypertension can result in an increase in 
afterload to the left ventricle, which may cause a reduction in 
the stroke volume, an elevation in the left ventricular filling 
pressure, and pulmonary congestion.13 The risk of myocardial 
ischemia, heart failure, stroke, neurocognitive dysfunction, 
renal failure, and bleeding are increased in patients with peri-
operative hypertension.14 In addition, adrenergic stimulation 
(occurring before, during, and after the operation) and activa-
tion of stress hormones and the renin–angiotensin system in 
both previously hypertensive and nonhypertensive patients 
may increase the risk of postoperative crises.8
Acute management of hypertensive 
emergencies and urgencies
Severely hypertensive patients without end-organ damage 
may be treated with an oral antihypertensive10 within 24 hours 
to several days in a closely monitored outpatient setting.15 
Patients with hypertensive emergencies require intensive BP 
control with intravenous antihypertensives,14 usually within 
1 hour of occurrence.15
On the basis of JNC-7 guidelines, the general   therapeutic 
goal is to lower the mean arterial pressure (MAP) by 
20%–25% within 60 minutes and, if the patient is then 
stable, to 160/100–110 mmHg over the next 2–6 hours.5 
Concomitantly, one should consider that an acute lowering 
of BP will reduce the blood flow to tissue without prompt 
compensatory vessel dilation, leading to ischemia of end-
organ tissue.11 Aortic dissection presents a different situation. 
The guideline followed in this case is to reduce the SBP to 
at least 120 mmHg within 20 minutes, with commensurate 
protection against reflex tachycardia.5 In APH in cardiac sur-
gery patients, treatment is recommended for a BP .140/90 
or a MAP $105 mmHg.16
Choice of agent
Many agents have been used to treat acute, severe elevations 
of BP, but despite having been used for years, most of these 
agents are not ideal across the broad range of   comorbidities. 
Intravenous antihypertensive agents available for the man-
agement of hypertensive emergencies fall into the broad 
categories of arterial vasodilators (hydralazine, fenoldopam, 
nicardipine, clevidipine, and enalaprilat), venous vasodila-
tors (nitroglycerin), mixed venous and arterial vasodilators 
(sodium nitroprusside), negative inotropic/chronotropic 
agents with (labetalol) or without vasodilator properties 
(esmolol), and α-adrenergic receptor blockers for increased 
sympathetic activity (phentolamine).
Intermittent intravenous labetalol is most often selected 
as the initial intravenous antihypertensive for patients with 
acute severe hypertension without stroke.17 Nicardipine is 
most often administered initially for patients with acute 
hemorrhagic stroke followed by intermittent intravenous 
labetalol and sodium nitroprusside.17
The main indications for sodium nitroprusside include 
hypertensive crises complicated by hypertensive enceph-
alopathy, heart failure, aortic dissection, and adrenergic 
crisis.15 It has a nonselective effect on both arterial and 
venous vessels, with rapid action within 1–2 minutes. How-
ever, hypotension is common, and tachyphylaxis may also 
develop. Often, rebound hypertension is seen with abrupt 
  withdrawal.18 Nitroglycerin is commonly used in hyperten-
sive crises complicated by ischemic heart disease and after 
coronary bypass.19 Its mechanism of action is through dila-
tion of the venous capacitance vessels, which also results in 
a decrease in preload.13 Drug tolerance is a common concern 
with nitroglycerin and sodium nitroprusside.20
Esmolol, a selective β-antagonist, has a high plasma clear-
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allowing for titration to the desired level. Esmolol has been 
commonly used during perioperative hypertension in cardiac 
surgery.21 It can be titrated to the desired effect because of 
its high plasma clearance and short half-life (approximately 
10 minutes). However, administration can result in a decrease 
in cardiac output (CO) rather than systemic vascular resis-
tance (SVR), which is most commonly the cause of elevated 
BP during cardiac surgery.20
Calcium channel blockers (CCBs) are a heterogeneous 
class of drugs used in the treatment of hypertension,   coronary 
artery disease (CAD), and dysrhythmias. There are 3 classes of 
calcium channels blockers: dihydropyridines (eg,   nicardipine, 
clevidipine), phenylalkylamines (eg, verapamil), and benzothi-
azepines (eg, diltiazem).22   Dihydropyridine-type calcium chan-
nel antagonists like nicardipine, isradipine, and nifedipine have 
been used successfully to control BP during cardiac surgery. 
They have little effect on heart rate without affecting myocar-
dial contractility because their effect is selective for vascular 
smooth muscle as opposed to the myocardium. They have little 
activity in the cardiac muscle or the sinoatrial node.23
The ideal agent for rapid control of BP would be an 
  arterial-specific vasodilator that has a rapid onset and offset, a 
low incidence of toxicity, and does not cause reflex tachycar-
dia.24 This article reviews the preclinical trials, pharmacologic 
and clinical efficacy, and tolerability of clevidipine butyrate 
(CleviprexTM; The Medicines Company, Parsippany, NJ, USA) 
and provides insights and evidence to support its clinical appli-
cability in managing emergent hypertensive conditions.
Clevidipine chemistry  
and formulation
Clevidipine butyrate is a mixture of 2 enantiomers: S-  clevidipine 
and R-clevidipine.9 It is a rapid-acting, dihydropyridine L-type 
calcium channel antagonist.13 These voltage-gated channels 
are expressed in several excitable cell types, including car-
diac and vascular cells, and mediate calcium influx during 
arterial smooth muscle membrane depolarization.25 The loss 
of extracellular calcium ion influx inhibits intracellular phos-
phodiesterase, which raises guanosine monophosphate levels, 
inhibiting vascular smooth muscle contractility, myocardial 
contractility, and cardiac conduction.6
Pharmacologic effects of clevidipine 
in animal studies
Clevidipine was found to decrease L-type calcium channel cur-
rent in guinea pig myocytes, suggesting that its primary mecha-
nism of action is the prevention of transmembrane   calcium 
influx.20 Clevidipine was also reported to be an   equipotent inhibi-
tor of spontaneous myogenic, neurogenic, and   agonist-induced 
contractions of the rat portal vein, further suggesting a common 
inhibitory pathway.20 The effect of clevidipine on spontaneous 
heart rate was studied in isolated Langendorff-perfused rat 
hearts and compared with those treated with isradipine and 
nifedipine.20 In contrast to nifedipine and isradipine, clevidipine 
did not interfere with spontaneous heart rate or atrioventricular 
conduction.26 The antihypertensive potency and the duration 
of action of clevidipine were compared with other compounds 
(nitroglycerin, sodium nitroprusside, felodipine, nicardipine, and 
isradipine) in anesthetized spontaneously hypertensive rats and 
normotensive rats. The recovery time after clevidipine admin-
istration was similar to that of nitroglycerin, longer than that of 
sodium nitroprusside, and considerably shorter than that of the 
calcium antagonists felodipine, isradipine, and nicardipine.20 
The effects of intravenous clevidipine, at increasing doses, on 
central hemodynamics of anesthetized dogs were compared with 
those of sodium nitroprusside. Clevidipine reduced mean aortic 
BP in a dose-dependent manner by decreasing total peripheral 
resistance. CO increased as a result of an increase in stroke 
volume while heart rate remained unaffected. Sodium nitroprus-
side decreased BP by decreasing CO through its venodilatory 
effect.27 The effect of clevidipine on ischemia/reperfusion-
related organ injuries has also been investigated. The possible 
protective effects of therapeutic and nontherapeutic doses of 
clevidipine were compared with that of a therapeutic dose of 
sodium nitroprusside in the rat model of splanchnic ischemia. 
Clevidipine was found to prevent the deterioration of mesenteric 
circulation during re-reperfusion after mesenteric ischemia.28 
Clevidipine was found to significantly reduce infarct size in pigs 
with myocardial ischemia when administered during the last 
10 minutes of ischemia and the first 5 minutes of reperfusion.29 
Clevidipine was reported to be effective in preserving renal 
reperfusion function in an experimental rat model of induced 
acute ischemic renal failure. Either clevidipine or fenoldopam, a 
dopamine D1-receptor agonist, was infused before reperfusion. 
Although no significant difference in glomerular filtration was 
observed between clevidipine and fenoldopam, clevidipine 
reduced losses in both sodium and water after reperfusion, sug-
gesting that clevidipine may have a protective effect on renal 
tubular function.30 The mechanisms of the protective action of 
clevidipine on ischemic organs are multifactorial, involving 
inhibition of oxygen-free radicals, calcium overload, and nitric 
oxide-related mechanisms.1,20
Clinical pharmacology of clevidipine
Clevidipine has been studied in healthy volunteers, patients 
with essential hypertension, and in anesthetized or sedated Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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patients during and after cardiac surgery.   Clevidipine has a 
rapid onset (2–4 minutes) and offset of action (5–15 minutes).20 
In cardiac surgery patients, the initial phase half-life is less 
than 1 minute, and its terminal half-life is approximately 4 
minutes.6 Clevidipine has exhibited greater inotropic than 
chronotropic selectivity.31 It exerts arterial-specific vasodila-
tory effects and is characterized by an ultrafast onset and offset 
of effect in   decreasing BP.32 The resting potential of vascular 
smooth muscle cells is less negative than that of the cardiac 
myocytes, which may partially explain the vascular selectivity 
of clevidipine.3
The ability of clevidipine to control BP in high-risk 
  cardiovascular surgery patients was observed to occur within 
1–2 minutes when administered in double-blind, placebo-
controlled trials.3,12 Clevidipine has minimal effect on venous 
vascular tone. Because of its selective afterload reduction, 
clevidipine increases CO with little influence on left ventricu-
lar filling pressure and pulmonary capillary wedge pressure.32 
Clevidipine may have diuretic properties due to a direct 
inhibitory effect on renal tubular reabsorption.33
In normotensive subjects, clevidipine was observed to 
cause a reduction in MAP, systemic vascular resistance, 
and pulmonary vascular resistance as well as an increase in 
stroke volume, with no change in heart rate or cardiac pre-
load.3 During 12 hours of clevidipine infusion, a significant 
decrease in MAP and SVR was observed in postcardiac sur-
gery patients at doses of $1.37 µg/kg/min, with no changes 
in heart rate, cardiac index, or cardiac filling pressure. The 
half-life remained less than 2 minutes.13 Clevidipine has 
been compared with sodium nitroprusside for the treatment 
of hypertension after coronary artery bypass graft (CABG) 
surgery. SVR and heart rate were found to be lower with 
clevidipine, whereas preload, stroke volume, and pulmonary 
vascular resistance were higher with clevidipine.12,34
Dosage
initial dose and titration
The starting dose of clevidipine is 1–2 mg/h, doubled every 
90 seconds until BP approaches the target (SBP reduced 
by $15%), then increased by less than double every 
5–10 minutes as target pressure approaches.35 An increase 
in infusion rate of 1–2 mg/h generally results in a decrease 
in SBP of approximately 2–4 mmHg.3 In addition, this drug 
can be safely used as an infusion for as long as 96 hours.2,36
Maintenance and maximum dose
The recommended maintenance dose is 4–6 mg/h as a con-
tinuous intravenous infusion for response in most patients. 
In clinical studies, most patients were treated with maximum 
doses of 16 mg/h, but patients with severe hypertension may 
require doses up to 32 mg/h (limited data are available at 
this dose).37 Clevidipine is commercially available in a lipid 
emulsion. Because of lipid-load restrictions, no more than 
1,000 mL or an average of 21 mg/h of clevidipine infusion 
is recommended per 24 hours.37 The efficacy and safety of 
clevidipine in pediatric patients (aged ,18 years) have not 
been established.3
Transition to oral
In cases where a transition to oral medication is desirable, 
clevidipine discontinuation or downward titration should take 
into account the time to onset of action of the oral therapy 
chosen.37
Pharmacokinetics
Clevidipine is practically insoluble in water and is available 
for clinical use as a lipid emulsion.14 Its half-life increases 
with lower blood temperature, and it is highly protein-bound 
in human plasma (∼99.7%).38 In the perioperative setting, 
clevidipine butyrate produced a 4%–5% decrease in SBP 
within 2–4 minutes after the initiation of an infusion at a dose 
of 1–2 mg/h.37 The time to onset of hemodynamic effects of 
clevidipine in healthy subjects was found to be within 2 min-
utes after start of infusion, and clevidipine reached arterial 
blood steady-state concentrations quickly.20
The action of clevidipine is independent of renal 
or hepatic functional status. Similar to esmolol, it is 
rapidly hydrolyzed by esterases in the blood and tis-
sues31 to a hemiacetal ester and butyric acid.9,20 These 
metabolites are subsequently metabolized to a large 
extent by decarboxylation before excretion through 
urine and fecal pathways.39 The same metabolites are 
formed after felodipine administration.9 Clevidipine 
has a mean blood flow clearance of 0.105 L/kg/min and 
a volume of distribution of 0.51 L/kg.1 Approximately 
90% of R-clevidipine is cleared in 8 minutes and 90% 
of S-clevidipine is cleared in 11 minutes.40 A lag time of 
0.5–1.0 minutes was observed between the termination 
of clevidipine infusion and the start of a rapid decay of 
clevidipine blood concentrations in venous blood samples 
collected from healthy volunteers and patients with 
essential hypertension.41 No lag time was observed in 
arterial blood samples from patients undergoing CABG 
surgery.42 Ericson et al43 reported that BP and heart rate 
return to predose values after discontinuation of the infu-
sion within 10 minutes in healthy volunteers.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Contraindications
Clevidipine is contraindicated in patients with allergies to 
soybeans, soy products, eggs, or egg products; patients with 
defective lipid metabolism (pathological hyperlipidemia, 
lipoid nephrosis, or acute pancreatitis, if it is accompanied 
by hyperlipidemia); and patients with severe aortic stenosis, 
in whom clevidipine may reduce myocardial oxygen delivery 
due to afterload reduction.37
Precautions and side effects
Clevidipine butyrate contains phospholipids that can support 
bacterial growth. Therefore, the vial must be changed every 
4 hours once punctured.6 Doses should be adjusted for elderly 
patients, starting at the low end of the dosing range. In clini-
cal trials, no differences in safety or effectiveness have been 
observed in patients older than 65 years compared with younger 
patients. Clevidipine may be initiated at 1–2 mg/h in patients 
with moderate to severe renal impairment and in patients 
with abnormal hepatic function, defined as one or more of 
the   following: elevated serum bilirubin, aspartate aminotrans-
ferase/serum glutamic oxaloacetic transaminase, or alanine 
  aminotransferase/serum glutamic pyruvic transaminase.3,37
Clevidipine is classified in Pregnancy Category C. Its 
effectiveness and safety have not been established in patients 
younger than 18 years.3
Cardiovascular side effects
Clevidipine may cause systemic hypotension and reflex tachy-
cardia. Patients who receive prolonged infusions of the new drug 
and are not switched to other antihypertensive agents should be 
monitored for rebound hypertension for at least 8 hours after 
discontinuation of the infusion.44 Patients with heart failure 
should be monitored closely because clevidipine, like other dihy-
dropyridine CCBs, can produce negative inotropic effects.37
During Efficacy Study of Clevidipine Assessing its 
Postoperative Antihypertensive Effect in Cardiac Surgery-2 
(ESCAPE-2) trial, a randomized, parallel, placebo-controlled, 
multicenter trial in cardiac surgery patients undergoing 
CABG (with or without valve replacement), atrial fibril-
lation was reported in 21% of patients with postoperative 
hypertension receiving intravenous clevidipine butyrate (over 
30–60 minutes) compared with 12% of patients   receiving pla-
cebo. No preoperative hypertension patients in The Efficacy 
Study of Clevidipine Assessing Its Preoperative Antihyperten-
sive Effect in Cardiac Surgery (ESCAPE-1) trial receiving cle-
vidipine butyrate or placebo experienced atrial fibrillation.44 
Cardiac arrest and myocardial infarction were reported in less 
than 1% of patients in the ECLIPSE trial.3,37
Renal side effects
During ESCAPE-1 trial, a randomized, parallel, placebo-con-
trolled, multicenter trial in cardiac surgery patients undergoing 
CABG (with or without valve replacement), acute renal failure 
was reported in 9% of patients with preoperative hypertension 
receiving intravenous clevidipine butyrate (over 30 minutes, 
until treatment failure or anesthesia induction occurred) com-
pared with 2% of patients receiving placebo. Acute renal failure 
was not reported among patients with postoperative hyperten-
sion receiving clevidipine butyrate (over 30–60 minutes) or in 
patients receiving placebo during the ESCAPE-2 trial.37
Therapeutic uses
Clevidipine butyrate injectable emulsion is indicated for 
the reduction of BP when oral therapy is not feasible or 
desirable.31
Therapeutic efficacy in acute severe 
hypertension, the VELOCITY trial
In the VELOCITY trial (EValuation of the Effect of 
ULtra-ShOrt-Acting Clevidipine in the Treatment of Patients 
with Severe HYpertension), Pollack et al2 evaluated the effect 
of ultrashort-acting clevidipine in the treatment of 131 patients 
with severe hypertension, defined as a SBP .180 mmHg and/
or DBP .115 mmHg, with or without end-organ injury. This 
trial was performed as a multicenter, open-label, single-arm 
study to assess the efficacy and safety of intravenous clevid-
ipine when initiated at a dose of 2 mg/h.
Patients who had been treated with an antihypertensive 
within 2 hours of the study or who were unlikely to tolerate 
intravenous antihypertensive treatment of .18 hours duration 
were excluded, as were those with cirrhosis, liver failure, aortic 
dissection, or acute hypertension caused by use of, or withdrawal 
from, illicit drugs or alcohol, or an overdose. Clevidipine was 
administered via intravenous infusion to patients in the emer-
gency department, an associated observation unit, or in ICU or 
coronary care units.2 The initial rate of administration was 2 mg/h 
for at least 3 minutes. After the initial titration, the agent was 
titrated on the basis of its efficacy, with a maximum infusion rate 
of 32 mg/h, until SBP reached the predetermined target range. 
Patients continued to receive clevidipine for 18–96 hours if SBP 
reached the target range within the initial 30-minute treatment 
period. If target range was not achieved during the initial 30 min-
utes, the use of additional intravenous antihypertensive agents 
was permitted with or without clevidipine. The mean total dose 
of clevidipine infused during the study was 206 mg.2
Clevidipine was shown to be a safe and effective medica-
tion for rapidly reducing severely increased BP and   controlling Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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BP for 18 hours or longer. The results indicated that in an 
emergency department setting, an initial nonweight-based dose 
of 2 mg/h is appropriate.2,3 The proportion of patients whose 
initial target SBP was achieved within the initial 30 minutes 
of starting the clevidipine infusion was defined as the primary 
efficacy end point. The proportion of patients whose SBP was 
reduced to below the lower limit of the initial target range 
within 3 minutes of the drug infusion (ie, overshoot hypoten-
sion) was defined as a primary safety end point. Successful 
transition to oral antihypertensive, defined as maintenance 
of SBP within the target range for 6 hours after clevidipine 
discontinuation, was a secondary end point.2,3
A SBP target range (spanning 10–40 mmHg) was 
determined for each eligible patient. The initial mean SBP 
target range was 142.9–174.7 mmHg. Approximately 90% 
of patients reached their SBP target within 30 minutes (the 
primary efficacy end point), which persisted for a minimum 
of 18 hours. The median time required to achieve target SBP 
was 9.5 minutes, consistent with other studies including 
ESCAPE-1 and -2 trials, which evaluated clevidipine com-
pared with placebo in preoperative and postoperative cardiac 
surgery patients.2 Five patients had a prespecified SBP target 
range wider (.40 mmHg) or narrower (,20 mmHg) than the 
defined protocol. Only 2 patients (1.6%) had SBP fall below 
the lower limit of the target range during the first 3 minutes 
of clevidipine infusion (primary safety end point). Among 
patients eligible for transition to oral therapy, 91.3% were 
successfully transitioned (secondary end point).3
Mean changes in SBP remained relatively steady throughout 
the drug infusion period (up to 60 hours), without increasing 
doses of clevidipine. Increase in baseline pulse rate was observed 
only during the first 15 minutes of infusion.2 The most common 
adverse effects reported were headache (6.3%),   nausea (4.8%), 
chest discomfort (3.2%), and vomiting (3.2%).2,37
Perioperative hypertension,  
the ECLIPSE, ESCAPE-1,  
and ESCAPE-2 trials
Clevidipine was found to be comparably effective to nitroglyc-
erin or sodium nitroprusside for the treatment of perioperative 
acute hypertension, or to nicardipine for postoperative hyperten-
sion, in patients undergoing cardiac surgery in the Evaluation 
of Clevidipine in the Perioperative Treatment of Hypertension 
Assessing Safety Events (ECLIPSE) trial.12 In the ESCAPE-1 
trial, clevidipine was comparably effective for the treatment of 
preoperative hypertension in patients undergoing cardiac surgery 
compared with 20% lipid placebo emulsion.32 In the ESCAPE-2 
trial, clevidipine was comparably effective for the treatment 
of postoperative hypertension in patients undergoing cardiac 
surgery compared with 20% lipid placebo emulsion.45
Clevidipine vs placebo in  
ESCAPE trials
The randomized, double-blind, placebo-controlled clinical 
trials (ESCAPE trials) demonstrated that clevidipine was 
safe and effective in controlling preoperative and postopera-
tive hypertensions in hypertensive cardiac surgery patients 
compared with placebo.32,45
Both preoperatively32 and postoperatively,45 the mean 
baseline BP did not differ significantly between the clevid-
ipine and placebo groups in either ESCAPE trial (mean SBP 
182 vs 177 mmHg and 147 vs 151 mmHg, respectively). 
A   history of previous myocardial infarction was more com-
mon in the clevidipine group, whereas angina pectoris and 
a family   history of CAD were less common in clevidipine 
recipients.32 The majority (84% of patients) of both clevid-
ipine and placebo recipients in ESCAPE-2 had a history of 
hypertension.
Patients received either intravenous clevidipine 0.5 mg/mL 
infused at an initial rate of 0.4 µg/kg/min or placebo for at 
least 30 minutes32,45 or until anesthesia was initiated,32 unless 
treatment failure occurred (primary end point: failure to 
reduce SBP by $15% from baseline or early and permanent 
discontinuation of treatment within 30 minutes of treatment 
initiation).32,45 Clevidipine was titrated as tolerated in doubling 
increments every 90 seconds up to 3.2 µg/kg/min. Infusion 
rates above 3.2 µg/kg/min were based on patient response and 
were allowed in serial increments of 1.5 µg/kg/min. Infusion 
rates between 4.4 and 8 µg/kg/min were administered for no 
longer than 2 hours, and no more than 500 mL of clevidipine 
infusion was administered in the first 24-hour period due to 
protocol-specified lipid-load restrictions.37,45
Clevidipine was effective in reducing preoperative32 and 
postoperative SBP.45 The treatment failure rate in the clevidipine 
group was 7.5%, compared with 82.7% in the placebo group, 
with no observed lack of efficacy in the   clevidipine group.32
The secondary outcome of time to reach the first measured 
reduction in SBP $15% from baseline was 6–8 minutes in 
the clevidipine group; the median time for the placebo group 
could not be estimated due to the small number of patients 
reaching the SBP target.32,45
The most common adverse effects reported in the clevid-
ipine groups compared with placebo were pyrexia (18.9% vs 
13.7%), atrial fibrillation (13.2% vs 11.8%), acute renal insuf-
ficiency/failure (9.4% vs 2%), and nausea (5.7% vs 9.8%), 
respectively. One death occurred in the clevidipine group Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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on postoperative day 1, which was attributed to mediastinal 
hemorrhage and not to the study drug.32,37
Clevidipine vs nicardipine 
hydrochloride, sodium 
nitroprusside, and nitroglycerin-the 
ECLIPSE trials
The ECLIPSE study consisted of 3 parallel trials conducted 
at many medical centers where patients aged 18 years or 
older undergoing cardiac surgery were randomly assigned 
to receive clevidipine or a comparator drug, nitroglycerin, 
sodium nitroprusside, or nicardipine.12,45 Clevidipine was 
found to be comparably effective to nitroglycerin or sodium 
nitroprusside for the treatment of perioperative acute hyper-
tension, and to nicardipine for postoperative hypertension, in 
patients undergoing cardiac surgery in these 3 prospective, 
randomized, open-label, parallel comparison trials.
During the initial 30 minutes of study, no other agents 
were permitted except in the case of treatment failure. If BP 
targets were not be achieved, alternative intravenous antihy-
pertensive agent could be used.3 Study drug was primarily 
initiated during the preoperative or intraoperative period in 
the clevidipine vs nitroglycerin and clevidipine vs sodium 
nitroprusside groups. The majority of patients who received 
preoperative or intraoperative antihypertensive treatment 
also received clevidipine vs nicardipine in the postopera-
tive setting per protocol, as the pharmacokinetic properties 
of nicardipine render it unsuitable for use in preoperative 
and intraoperative settings.12,45 BP excursions were defined 
as the time and extent to which SBP exceeded or fell below 
individualized predetermined BP ranges.12
Clevidipine was initiated at an infusion rate of 0.4 µg/kg/min 
and was titrated as tolerated in doubling increments every 
90 seconds up to 3.2 µg/kg/min. Infusion rates above 3.2 µg/kg/min 
were based on patient response and were allowed in serial incre-
ments of 1.5 µg/kg/min. Infusion rates between 4.4 and 8 µg/kg/
min were used for no longer than 2 hours, and no more than 500 
mL of clevidipine was administered in the first 24-h period due 
to protocol-specified lipid-load restrictions.12,37
No differences were observed between patients receiving 
clevidipine compared with nitroglycerin, sodium nitroprus-
side, or nicardipine in the primary outcome of the 30-day 
incidence of death, stroke, myocardial infarction, or renal 
dysfunction. However, clevidipine was more effective at 
keeping BP within the prespecified range.37 Clevidipine 
was consistently predictable in controlling BP (with 
almost half of the BP excursions of the other agents; 3.8 vs 
7.8 mmHg × min/h) because its fast onset and offset of action 
allowed for easy titration to maintain the target BP range in 
cardiac surgery patients with acute hypertension.12
The most commonly reported adverse events included 
atrial fibrillation and sinus tachycardia, which were similar in 
incidence for clevidipine and the comparator drugs. Atrial fibril-
lation was reported at 33.6% vs 32% (  clevidipine vs nitroglyc-
erin), 36.1% vs 32.2% (clevidipine vs sodium   nitroprusside), 
and 35.6% vs 35.2% (clevidipine vs nicardipine).12,37,39
Conclusion
The rapid recognition and initiation of therapy are keys to 
minimize end-organ damage in patients with hypertensive 
emergency. Clevidipine is a vasoselective, ultrashort-acting, 
dihydropyridine L-type calcium channel antagonist with a rapid 
onset and offset of action, indicated for the reduction of BP when 
oral therapy is not feasible or desired. Clevidipine butyrate is an 
injectable emulsion, with pharmacokinetic and pharmacological 
properties that are well suited for acute BP control. Clevidipine 
has been shown to induce dose- and concentration-dependent 
decreases in mean arterial BP and SVR, with a little effect on 
heart rate and no effect on venous capacitance vessels.
Clevidipine has been shown to be a safe and effective medi-
cation for rapidly reducing severely increased BP and control-
ling BP for 18 hours or longer in emergency   departments or 
associated observation units, or in ICU or coronary care units. 
Studies demonstrated that clevidipine was comparably effective 
to nitroglycerin or sodium nitroprusside for the treatment of peri-
operative acute hypertension, or to nicardipine for postoperative 
hypertension, in patients undergoing cardiac surgery.
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